SYK
Stryker Corporation
Healthcare · Medical Devices · United States · Stock
Score Breakdown
Scored for Dividend Income profile
Sub-scores are 0–20 each; Model Score is weighted by your selected investment goal. How it works →
Why Ranked Here
- The composite score of 58.0 is anchored by a very strong dividend sub-score (18.8/20), which alone places Stryker among reliable income-oriented research candidates, while the other sub-scores pull the total toward a mid-range outcome.
- Financial health (14.0/20) and profitability (13.2/20) both score above the midpoint, confirming that Stryker's fundamentals are sound and its balance sheet is not under stress, contributing meaningfully to the overall score without being exceptional.
- The growth sub-score (12.5/20) and especially the momentum sub-score (7.4/20) anchor the total below 65, reflecting a large-cap medical device company growing steadily but not rapidly, with limited evidence of accelerating quarterly performance in the most recent fiscal year.
Why Not Higher
- The theme sub-score of 0.0 out of 20 represents a full 20-point ceiling that was never reached, and had even partial theme exposure been identified, the composite score could have risen meaningfully toward the 70-plus range.
- The momentum sub-score of 7.4 out of 20 is the weakest operationally derived metric in the model, signaling that sequential quarterly improvements in core financial metrics have not been strong enough to boost the overall score, despite a healthy balance sheet and income profile.
Data Confidence
10 / 10
Very High — full data coverage
Research Summary
AI-generated analysis reflects data and conditions as of the report date shown above. Verify any specific figures through primary sources before acting on this analysis.
Stryker Corporation is a leading U.S.-based medical device manufacturer operating across two primary segments: MedSurg and Neurotechnology & Spine, and Orthopaedics. The company produces a broad portfolio of surgical equipment, implants, endoscopy systems, patient handling products, and neurovascular devices, making it one of the most diversified large-cap medical device companies in the world. Its products serve hospitals, ambulatory surgery centers, and healthcare systems globally, underpinning a relatively stable demand profile tied to elective and emergency surgical procedures. Stryker's composite model score of 58.0/100 reflects a company with genuine strengths in dividend reliability and financial health, partially offset by softer momentum and a complete absence of macro theme exposure in the scoring model. The dividend sub-score of 18.8 out of 20 is the standout result, indicating strong free cash flow payout discipline, consistent dividend-per-share growth, and durable FCF coverage — hallmarks of a mature, cash-generative business. Financial health (14.0/20) and profitability (13.2/20) reinforce the picture of a well-managed balance sheet with adequate interest coverage and solid operating margins. Growth (12.5/20) is moderate, reflecting steady but not explosive top-line and earnings expansion consistent with a large-cap incumbent. The central research tradeoff for Stryker is the tension between its best-in-model dividend income profile (scoring 70.2 on that goal profile) and its weakest aggressive-growth profile (51.1). The theme score of 0.0/20 is a meaningful drag — the model found no identifiable macro theme tailwinds (such as AI, renewable energy, or emerging-market infrastructure) — which limits its appeal for thematic or growth-oriented research mandates. Researchers evaluating Stryker should weigh its demonstrated income consistency and balance sheet stability against limited momentum signals and the absence of thematic re-rating catalysts.
Plain English
Stryker makes the surgical tools, joint replacement implants, and hospital beds that operating rooms around the world depend on every day. A model score of 58.0 out of 100 means it's a solid, well-run company but not a standout across every dimension — it scores particularly well for dividend reliability and financial health, but loses ground on business momentum and macro theme exposure. The Medium risk rating reflects that while Stryker has stable revenues and manageable debt, it operates in a competitive, regulation-heavy industry where pricing pressure and acquisition integration can create uncertainty. For researchers focused on consistent dividend income rather than rapid growth, the data positions Stryker as a research candidate worth examining more closely.
Bull Case vs. Bear Case
Bull Case
- The dividend sub-score of 18.8 out of 20 — the highest individual sub-score in the model — signals strong free cash flow coverage of dividends, a multi-year streak of dividend-per-share increases, and disciplined FCF payout management, supporting the research case for durable income generation.
- Financial health scores 14.0 out of 20, indicating that Stryker maintains a leverage ratio and interest coverage profile consistent with an investment-grade balance sheet capable of funding both organic growth and continued dividend payments.
- The profitability sub-score of 13.2 out of 20 reflects competitive net and operating margins alongside positive return on assets, consistent with a company that converts a meaningful share of its revenue into profit even across a diverse and complex product portfolio.
Bear Case
- The momentum sub-score of 7.4 out of 20 — the weakest operationally derived sub-score — suggests that sequential quarterly improvements in revenue, earnings, and margins have been limited or inconsistent in the most recent filing period, reducing near-term conviction in accelerating fundamentals.
- The theme score of 0.0 out of 20 means the model identified no meaningful macro tailwind exposure for Stryker, limiting its appeal to researchers seeking companies positioned to benefit from structural growth themes such as digitization, AI integration, or demographic-driven demand shifts.
- The growth sub-score of 12.5 out of 20 reflects moderate year-over-year revenue, net income, and EPS expansion, suggesting Stryker's scale may constrain the kind of high-rate organic growth that would re-rate it toward more aggressive research mandates.
What Could Change the Picture
Bullish Triggers
- A measurable improvement in the momentum sub-score in a subsequent filing — driven by accelerating sequential quarterly revenue growth or margin expansion — would suggest Stryker's fundamentals are re-accelerating and could support a higher composite score.
- Identification of macro theme exposure in a future model update — for example, through demonstrable AI-enabled surgical robotics adoption or demographic-driven procedure volume growth — would address the 0.0 theme score and materially improve the overall research profile.
Bearish Triggers
- A deterioration in the financial health sub-score driven by increased leverage from large acquisitions or weakening interest coverage ratios would undermine one of Stryker's current scoring strengths and raise the risk profile above Medium.
- A decline in the dividend sub-score — whether from FCF compression, a reduction in dividend-per-share growth rate, or deteriorating FCF payout coverage — would weaken the primary argument for Stryker as a dividend income research candidate and reduce the composite score significantly.
Red Flags
- The momentum sub-score of 7.4 out of 20 is notably low relative to other sub-scores, which may indicate margin or earnings deterioration on a sequential quarterly basis that warrants closer examination of the underlying 10-K segment data.
- A theme score of 0.0 out of 20 means the model assigns no credit for macro tailwinds, which could reflect a business model that is exposed to cyclical procedure volumes and healthcare budget pressures without clear structural growth levers beyond its existing markets.
Risk Profile
Medium RiskThe Medium risk rating for Stryker reflects a company with a stable, diversified medical device business and a sound balance sheet, but one that operates in an environment subject to regulatory scrutiny, product liability exposure, pricing pressure from hospital systems, and integration risk from its historically acquisitive growth strategy. While the financial health score does not flag acute balance sheet stress, the combination of moderate leverage and a competitive industry landscape means that adverse macro or regulatory events could pressure margins and cash flow in ways that are not fully predictable from current filing data.
Key Catalysts to Watch
The most important metrics to monitor for Stryker are sequential quarterly improvements in revenue and operating margins — the key drivers of the currently weak momentum sub-score — as any sustained acceleration would directly improve the model's assessment of near-term fundamental trajectory. Researchers should also watch for any developments in surgical robotics or digital health integration within Stryker's product pipeline, as these could eventually trigger macro theme credit in future model versions and re-rate the overall research profile.
This report is for educational and research purposes only. It does not constitute financial, investment, legal, or tax advice — always conduct your own due diligence before making investment decisions.